HIV-1 Integrase Polymorphisms Are Associated with Prior Antiretroviral Drug Exposure

Overview

Journal Retrovirology

Publisher Biomed Central

Specialty Microbiology

Date 2009 Feb 11

PMID 19203393

Citations 11

Authors

Sebastiaan J van Hal

Belinda Herring

Zaquan Deris

Bin Wang

Nitin K Saksena

Dominic E Dwyer

Affiliations

Soon will be listed here.

Abstract

In a recent summary of integrase sequences, primary integrase inhibitor mutations were rare. In a review of integrase inhibitor-naïve Australian HIV-1 sequences, primary mutations were not identified, although the accessory mutation G140S was detected. A link with previous antiretroviral therapy, intra-subtype B divergence across the integrase gene and transmission of integrase polymorphisms were also noted. Based on these findings, we would recommend ongoing surveillance of integrase mutations, and integrase region sequencing for patients prior to commencement of integrase inhibitors.

Citing Articles

Pre-Treatment Integrase Inhibitor Resistance and Natural Polymorphisms among HIV-1 Subtype C Infected Patients in Ethiopia.

Arimide D, Szojka Z, Zealiyas K, Gebreegziabxier A, Adugna F, Sasinovich S Viruses. 2022; 14(4).

PMID: 35458459 PMC: 9029575. DOI: 10.3390/v14040729.

Relationship between HIV integrase polymorphisms and integrase inhibitor susceptibility: An analysis.

Hutapea H, Maladan Y, Widodo Heliyon. 2018; 4(12):e00956.

PMID: 30534615 PMC: 6278726. DOI: 10.1016/j.heliyon.2018.e00956.

Prevalence of resistance to integrase strand-transfer inhibitors (INSTIs) among untreated HIV-1 infected patients in Morocco.

Alaoui N, El Alaoui M, Touil N, Annaz H, Melloul M, Tagajdid R BMC Res Notes. 2018; 11(1):369.

PMID: 29884219 PMC: 5994051. DOI: 10.1186/s13104-018-3492-5.

Lack of impact of pre-existing T97A HIV-1 integrase mutation on integrase strand transfer inhibitor resistance and treatment outcome.

Abram M, Ram R, Margot N, Barnes T, White K, Callebaut C PLoS One. 2017; 12(2):e0172206.

PMID: 28212411 PMC: 5315389. DOI: 10.1371/journal.pone.0172206.

Effect of HIV-1 Subtype C integrase mutations implied using molecular modeling and docking data.

Sachithanandham J, Reddy K, Solomon K, David S, Singh S, Ramalingam V Bioinformation. 2017; 12(3):221-230.

PMID: 28149058 PMC: 5267967. DOI: 10.6026/97320630012221.

References

Cooper D, Steigbigel R, Gatell J, Rockstroh J, Katlama C, Yeni P . Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008; 359(4):355-65. DOI: 10.1056/NEJMoa0708978. View

Myers R, Pillay D . Analysis of natural sequence variation and covariation in human immunodeficiency virus type 1 integrase. J Virol. 2008; 82(18):9228-35. PMC: 2546890. DOI: 10.1128/JVI.01535-07. View

Steigbigel R, Cooper D, Kumar P, Eron J, Schechter M, Markowitz M . Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008; 359(4):339-54. DOI: 10.1056/NEJMoa0708975. View

Delelis O, Malet I, Na L, Tchertanov L, Calvez V, Marcelin A . The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Res. 2009; 37(4):1193-201. PMC: 2651800. DOI: 10.1093/nar/gkn1050. View

Rhee S, Liu T, Kiuchi M, Zioni R, Gifford R, Holmes S . Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors. Retrovirology. 2008; 5:74. PMC: 2546438. DOI: 10.1186/1742-4690-5-74. View